ArticleCurrent diabetes reports2009
Management of diabetes in dialysis patients.
Article in Current diabetes reports, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 14 citations in OpenAlex.
- Glycemic instability in renal decline: a review of HbA1c variability and outcomes in chronic kidney disease.Diabetology & metabolic syndrome · 2026Review
- Perceptions of caregivers regarding engagement with integrated management of chronic kidney disease patients in selected public hospitals of KwaZulu-Natal region, South Africa.Health SA = SA Gesondheid · 2018Article
- Current therapeutic approaches in the management of hyperglycemia in chronic renal disease.Reviews in endocrine & metabolic disorders · 2017Review
- Flash Glucose Monitoring in Subjects with Diabetes on Hemodialysis: A Pilot Study.Indian journal of endocrinology and metabolismArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetes mellitus is the most common cause of kidney disease worldwide, and of end-stage renal disease (ESRD) in the United States and elsewhere. Mortality rates of patients with diabetes mellitus (DM) on chronic dialysis exceed those of non-DM patients. ESRD and dialysis add to the complexity of glycemic management in this population. Abnormal glucoregulation includes reduced insulin sensitivity and renal clearance of the hormone. Implementation of dialysis affects glucose and insulin levels, while increasing insulin sensitivity. Tight glycemic control carries an increased risk of hypoglycemia in ESRD. Monitoring glycemic control with hemoglobin A(1c) (HbA(1c)) levels may be suboptimal because of analytical and clinical variability of the test. Recent studies on HbA(1c) and clinical outcomes in this population present complementary results on the role of glycemic control in patients with DM with ESRD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.